

RNS Number : 6228R  
Genedrive PLC  
30 December 2024

**genedrive plc**  
**("genedrive" or the "Company")**

**Result of AGM**

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.

For information, details of the proxy voting are shown below:

Resolution	Votes For	Votes For (as % of votes cast)	Votes Against	Votes Against (as % of votes cast)	Vote Withheld
1	60,337,408	96.9%	1,932,301	3.1%	44,070
2	54,051,527	89.5%	6,370,692	10.5%	1,891,560
3	56,234,467	90.4%	5,972,194	9.6%	107,118
4	56,232,855	90.4%	5,973,806	9.6%	107,118
5	54,614,002	89.9%	6,155,707	10.1%	1,544,070
6	56,585,659	90.9%	5,684,050	9.1%	44,070
7	41,714,611	67.0%	20,555,098	33.0%	44,070
8	58,270,899	93.6%	3,980,810	6.4%	62,070
9	52,909,558	87.3%	7,705,575	12.7%	1,698,646
10	49,491,977	81.7%	11,079,156	18.3%	1,742,646
11	52,535,894	86.7%	8,035,239	13.3%	1,742,646

The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website ([www.genedriveplc.com](http://www.genedriveplc.com)).

Although all the resolutions were passed, the Board of genedrive notes that more than 20% of votes were cast against the reappointment of one of the directors. While the Board believes that this director brings considerable experience and expertise to the Board, it intends to engage with shareholders to better understand their concerns on the resolution in question.

For further details please contact:

**genedrive plc** +44 (0)161 989 0245  
Gino Miele: CEO / Russ Shaw: CFO

**Peel Hunt LLP (Nominated Adviser and Broker)** +44 (0)20 7418 8900  
James Steel / Patrick Birkholm

**Walbrook PR Ltd (Media & Investor Relations)** +44 (0)20 7933 8780 or [genedrive@walbrookpr.com](mailto:genedrive@walbrookpr.com)  
Anna Dunphy +44 (0)7876 741 001

**About genedrive plc** (<http://www.genedriveplc.com>)

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS.

The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGBBBDDDBUXDGSG